APO Research
Talk to an analyst

APO RESEARCH · REPORT

CRISPR and CRISPR-Associated (Cas) Genes

This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.

Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid.

The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.

Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.

By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.

Selected research

Market Analysis & Forecast

Global CRISPR and CRISPR-Associated (Cas) Genes Market Analysis and Forecast 2026-2032

2 January 2026193 pages

Choose your research edition.

Industry ResearchCRISPR and CRISPR-Associated (Cas) Genes Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal CRISPR and CRISPR-Associated (Cas) Genes Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal CRISPR and CRISPR-Associated (Cas) Genes Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CRISPR and CRISPR-Associated (Cas) Genes Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal CRISPR and CRISPR-Associated (Cas) Genes Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

This report studies the CRISPR And CRISPR-Associated (Cas) Genes market.

Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid.

The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.

Read the full market overview

Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down.

By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline.

Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics and Intellia therapeutics, Inc. are the top 5 players of CRISPR and CRISPR-Associated (Cas) Genes, with about 63% market shares.

CRISPR And CRISPR-Associated (Cas) Genes industry is relatively concentrated, manufacturers are mostly in the Europe and North America. Among them, North America region accounted for more than 45% of the total market of global CRISPR And CRISPR-Associated (Cas) Genes.

Report Includes

This report presents an overview of global market for CRISPR and CRISPR-Associated (Cas) Genes, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of CRISPR and CRISPR-Associated (Cas) Genes, also provides the revenue of main regions and countries. Of the upcoming market potential for CRISPR and CRISPR-Associated (Cas) Genes, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CRISPR and CRISPR-Associated (Cas) Genes revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CRISPR and CRISPR-Associated (Cas) Genes market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CRISPR and CRISPR-Associated (Cas) Genes revenue, projected growth trends, production technology, application and end-user industry.

CRISPR and CRISPR-Associated (Cas) Genes Segment by Company

Thermo Fisher Scientific

Editas Medicine

Caribou Biosciences

CRISPR therapeutics

Intellia therapeutics, Inc.

Cellectis

Horizon Discovery Plc

Sigma Aldrich

Precision Biosciences

Genscript

Sangamo Biosciences Inc.

Lonza Group Limited

Integrated DNA Technologies

New England Biolabs

Origene Technologies

CRISPR and CRISPR-Associated (Cas) Genes Segment by Type

Genome Editing

Genetic engineering

gRNA Database/Gene Librar

CRISPR Plasmid

Human Stem Cells

Genetically Modified Organisms/Crops

Cell Line Engineering

CRISPR and CRISPR-Associated (Cas) Genes Segment by Application

Biotechnology Companies

Pharmaceutical Companies

Academic Institutes

Research and Development Institutes

CRISPR and CRISPR-Associated (Cas) Genes Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CRISPR and CRISPR-Associated (Cas) Genes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CRISPR and CRISPR-Associated (Cas) Genes and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CRISPR and CRISPR-Associated (Cas) Genes.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of CRISPR and CRISPR-Associated (Cas) Genes in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of CRISPR and CRISPR-Associated (Cas) Genes company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CRISPR and CRISPR-Associated (Cas) Genes revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Genome Editing Major Player Table 3. Genetic engineering Major Player Table 4. gRNA Database/Gene Librar Major Player Table 5. CRISPR Plasmid Major Player Table 6. Human Stem Cells Major Player Table 7. Genetically Modified Organisms/Crops Major Player Table 8. Cell Line Engineering Major Player Table 9. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Biotechnology Companies Major Player Table 11. Pharmaceutical Companies Major Player Table 12. Academic Institutes Major Player Table 13. Research and Development Institutes Major Player Table 14. CRISPR and CRISPR-Associated (Cas) Genes Industry Trends Table 15. CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers Table 16. CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges Table 17. CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints Table 18. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 19. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2021-2026) & (US$ Million) Table 20. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Region (2021-2026) Table 21. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2027-2032) & (US$ Million) Table 22. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Region (2027-2032) Table 23. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Players (US$ Million) & (2021-2026) Table 24. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Players (2021-2026) Table 25. Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Ranking, 2024 VS 2025 VS 2026 Table 26. Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Headquarters & Area Served Table 27. Global CRISPR and CRISPR-Associated (Cas) Genes Players, Product Type & Application Table 28. Global CRISPR and CRISPR-Associated (Cas) Genes Players Establishment Date Table 29. Global Players Market Concentration Ratio (CR5 and HHI) Table 30. Global CRISPR and CRISPR-Associated (Cas) Genes by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 31. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026) & (US$ Million) Table 33. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032) & (US$ Million) Table 34. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2021-2026) Table 35. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2027-2032) Table 36. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026) & (US$ Million) Table 38. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032) & (US$ Million) Table 39. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2021-2026) Table 40. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2027-2032) Table 41. Thermo Fisher Scientific Company Information Table 42. Thermo Fisher Scientific Business Overview Table 43. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 45. Thermo Fisher Scientific Recent Development Table 46. Editas Medicine Company Information Table 47. Editas Medicine Business Overview Table 48. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 50. Editas Medicine Recent Development Table 51. Caribou Biosciences Company Information Table 52. Caribou Biosciences Business Overview Table 53. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 55. Caribou Biosciences Recent Development Table 56. CRISPR therapeutics Company Information Table 57. CRISPR therapeutics Business Overview Table 58. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 60. CRISPR therapeutics Recent Development Table 61. Intellia therapeutics, Inc. Company Information Table 62. Intellia therapeutics, Inc. Business Overview Table 63. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 65. Intellia therapeutics, Inc. Recent Development Table 66. Cellectis Company Information Table 67. Cellectis Business Overview Table 68. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 70. Cellectis Recent Development Table 71. Horizon Discovery Plc Company Information Table 72. Horizon Discovery Plc Business Overview Table 73. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 75. Horizon Discovery Plc Recent Development Table 76. Sigma Aldrich Company Information Table 77. Sigma Aldrich Business Overview Table 78. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 80. Sigma Aldrich Recent Development Table 81. Precision Biosciences Company Information Table 82. Precision Biosciences Business Overview Table 83. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 85. Precision Biosciences Recent Development Table 86. Genscript Company Information Table 87. Genscript Business Overview Table 88. Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 90. Genscript Recent Development Table 91. Sangamo Biosciences Inc. Company Information Table 92. Sangamo Biosciences Inc. Business Overview Table 93. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 95. Sangamo Biosciences Inc. Recent Development Table 96. Lonza Group Limited Company Information Table 97. Lonza Group Limited Business Overview Table 98. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 99. Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 100. Lonza Group Limited Recent Development Table 101. Integrated DNA Technologies Company Information Table 102. Integrated DNA Technologies Business Overview Table 103. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 104. Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 105. Integrated DNA Technologies Recent Development Table 106. New England Biolabs Company Information Table 107. New England Biolabs Business Overview Table 108. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 109. New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 110. New England Biolabs Recent Development Table 111. Origene Technologies Company Information Table 112. Origene Technologies Business Overview Table 113. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 114. Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio Table 115. Origene Technologies Recent Development Table 116. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026) & (US$ Million) Table 117. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032) & (US$ Million) Table 118. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026) & (US$ Million) Table 119. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032) & (US$ Million) Table 120. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021-2026) & (US$ Million) Table 122. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (US$ Million) & (2027-2032) Table 123. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026) & (US$ Million) Table 124. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032) & (US$ Million) Table 125. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026) & (US$ Million) Table 126. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032) & (US$ Million) Table 127. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021-2026) & (US$ Million) Table 129. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (US$ Million) & (2027-2032) Table 130. China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026) & (US$ Million) Table 131. China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032) & (US$ Million) Table 132. China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026) & (US$ Million) Table 133. China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032) & (US$ Million) Table 134. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026) & (US$ Million) Table 135. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032) & (US$ Million) Table 136. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026) & (US$ Million) Table 137. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032) & (US$ Million) Table 138. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Region (US$ Million) & (2021-2026) Table 140. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Region (US$ Million) & (2027-2032) Table 141. SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026) & (US$ Million) Table 142. SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032) & (US$ Million) Table 143. SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026) & (US$ Million) Table 144. SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032) & (US$ Million) Table 145. SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021-2026) & (US$ Million) Table 147. SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (US$ Million) & (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. CRISPR and CRISPR-Associated (Cas) Genes Image Figure 2. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Share 2021 VS 2025 VS 2032 Figure 4. Genome Editing Image Figure 5. Genetic engineering Image Figure 6. gRNA Database/Gene Librar Image Figure 7. CRISPR Plasmid Image Figure 8. Human Stem Cells Image Figure 9. Genetically Modified Organisms/Crops Image Figure 10. Cell Line Engineering Image Figure 11. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size Share 2021 VS 2025 VS 2032 Figure 13. Biotechnology Companies Image Figure 14. Pharmaceutical Companies Image Figure 15. Academic Institutes Image Figure 16. Research and Development Institutes Image Figure 17. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size (US$ Million) & (2021-2032) Figure 18. Global CRISPR and CRISPR-Associated (Cas) Genes Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global CRISPR and CRISPR-Associated (Cas) Genes Market Share by Region: 2021 VS 2025 VS 2032 Figure 20. Global CRISPR and CRISPR-Associated (Cas) Genes Players Revenue Share Top 10 and Top 5 in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2021-2032) Figure 25. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 27. Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2021-2032) Figure 28. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032) Figure 30. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032) Figure 31. North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Country (2021-2032) Figure 32. United States CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Canada CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Mexico CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (2021-2032) & (US$ Million) Figure 36. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032) Figure 37. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032) Figure 38. Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Country (2021-2032) Figure 39. Germany CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. France CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. U.K. CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Italy CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Spain CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Russia CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Netherlands CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Nordic Countries CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. China CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. China CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032) Figure 49. China CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032) Figure 50. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (2021-2032) & (US$ Million) Figure 51. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032) Figure 52. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032) Figure 53. Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Region (2021-2032) Figure 54. Japan CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. South Korea CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. India CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Australia CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Taiwan CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Southeast Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (2021-2032) & (US$ Million) Figure 61. SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032) Figure 62. SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032) Figure 63. SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Country (2021-2032) Figure 64. Brazil CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Argentina CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Chile CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Colombia CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Peru CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Saudi Arabia CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Israel CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. UAE CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Turkey CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Iran CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Egypt CRISPR and CRISPR-Associated (Cas) Genes Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Genome Editing
  • Genetic engineering
  • gRNA Database/Gene Librar
  • CRISPR Plasmid
  • Human Stem Cells
  • Genetically Modified Organisms/Crops
  • Cell Line Engineering
Applications
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Academic Institutes
  • Research and Development Institutes
Companies covered
  • Thermo Fisher Scientific
  • Editas Medicine
  • Caribou Biosciences
  • CRISPR therapeutics
  • Intellia therapeutics, Inc.
  • Cellectis
  • Horizon Discovery Plc
  • Sigma Aldrich
  • Precision Biosciences
  • Genscript
  • Sangamo Biosciences Inc.
  • Lonza Group Limited
  • Integrated DNA Technologies
  • New England Biolabs
  • Origene Technologies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 CRISPR and CRISPR-Associated (Cas) Genes Market by Type
  3. 1.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Genome Editing
  5. 1.2.3 Genetic engineering
  6. 1.2.4 gRNA Database/Gene Librar
  7. 1.2.5 CRISPR Plasmid
  8. 1.2.6 Human Stem Cells
  9. 1.2.7 Genetically Modified Organisms/Crops
  10. 1.2.8 Cell Line Engineering
  11. 1.3 CRISPR and CRISPR-Associated (Cas) Genes Market by Application
  12. 1.3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Biotechnology Companies
  14. 1.3.3 Pharmaceutical Companies
  15. 1.3.4 Academic Institutes
  16. 1.3.5 Research and Development Institutes
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 CRISPR and CRISPR-Associated (Cas) Genes Market Dynamics
  1. 2.1 CRISPR and CRISPR-Associated (Cas) Genes Industry Trends
  2. 2.2 CRISPR and CRISPR-Associated (Cas) Genes Industry Drivers
  3. 2.3 CRISPR and CRISPR-Associated (Cas) Genes Industry Opportunities and Challenges
  4. 2.4 CRISPR and CRISPR-Associated (Cas) Genes Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Perspective (2021-2032)
  2. 3.2 Global CRISPR and CRISPR-Associated (Cas) Genes Growth Trends by Region
  3. 3.2.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2021-2026)
  5. 3.2.3 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Players
  2. 4.1.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Players (2021-2026)
  3. 4.1.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global CRISPR and CRISPR-Associated (Cas) Genes Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global CRISPR and CRISPR-Associated (Cas) Genes Key Players Headquarters & Area Served
  7. 4.4 Global CRISPR and CRISPR-Associated (Cas) Genes Players, Product Type & Application
  8. 4.5 Global CRISPR and CRISPR-Associated (Cas) Genes Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market CR5 and HHI
  11. 4.6.3 2025 CRISPR and CRISPR-Associated (Cas) Genes Tier 1, Tier 2, and Tier 3
5 CRISPR and CRISPR-Associated (Cas) Genes Market Size by Type
  1. 5.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2032)
  3. 5.3 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2021-2032)
6 CRISPR and CRISPR-Associated (Cas) Genes Market Size by Application
  1. 6.1 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2032)
  3. 6.3 Global CRISPR and CRISPR-Associated (Cas) Genes Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Thermo Fisher Scientific
  2. 7.1.1 Thermo Fisher Scientific Company Information
  3. 7.1.2 Thermo Fisher Scientific Business Overview
  4. 7.1.3 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Thermo Fisher Scientific CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  6. 7.1.5 Thermo Fisher Scientific Recent Developments
  7. 7.2 Editas Medicine
  8. 7.2.1 Editas Medicine Company Information
  9. 7.2.2 Editas Medicine Business Overview
  10. 7.2.3 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Editas Medicine CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  12. 7.2.5 Editas Medicine Recent Developments
  13. 7.3 Caribou Biosciences
  14. 7.3.1 Caribou Biosciences Company Information
  15. 7.3.2 Caribou Biosciences Business Overview
  16. 7.3.3 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Caribou Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  18. 7.3.5 Caribou Biosciences Recent Developments
  19. 7.4 CRISPR therapeutics
  20. 7.4.1 CRISPR therapeutics Company Information
  21. 7.4.2 CRISPR therapeutics Business Overview
  22. 7.4.3 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  23. 7.4.4 CRISPR therapeutics CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  24. 7.4.5 CRISPR therapeutics Recent Developments
  25. 7.5 Intellia therapeutics, Inc.
  26. 7.5.1 Intellia therapeutics, Inc. Company Information
  27. 7.5.2 Intellia therapeutics, Inc. Business Overview
  28. 7.5.3 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Intellia therapeutics, Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  30. 7.5.5 Intellia therapeutics, Inc. Recent Developments
  31. 7.6 Cellectis
  32. 7.6.1 Cellectis Company Information
  33. 7.6.2 Cellectis Business Overview
  34. 7.6.3 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Cellectis CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  36. 7.6.5 Cellectis Recent Developments
  37. 7.7 Horizon Discovery Plc
  38. 7.7.1 Horizon Discovery Plc Company Information
  39. 7.7.2 Horizon Discovery Plc Business Overview
  40. 7.7.3 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Horizon Discovery Plc CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  42. 7.7.5 Horizon Discovery Plc Recent Developments
  43. 7.8 Sigma Aldrich
  44. 7.8.1 Sigma Aldrich Company Information
  45. 7.8.2 Sigma Aldrich Business Overview
  46. 7.8.3 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sigma Aldrich CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  48. 7.8.5 Sigma Aldrich Recent Developments
  49. 7.9 Precision Biosciences
  50. 7.9.1 Precision Biosciences Company Information
  51. 7.9.2 Precision Biosciences Business Overview
  52. 7.9.3 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Precision Biosciences CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  54. 7.9.5 Precision Biosciences Recent Developments
  55. 7.10 Genscript
  56. 7.10.1 Genscript Company Information
  57. 7.10.2 Genscript Business Overview
  58. 7.10.3 Genscript CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Genscript CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  60. 7.10.5 Genscript Recent Developments
  61. 7.11 Sangamo Biosciences Inc.
  62. 7.11.1 Sangamo Biosciences Inc. Company Information
  63. 7.11.2 Sangamo Biosciences Inc. Business Overview
  64. 7.11.3 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sangamo Biosciences Inc. CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  66. 7.11.5 Sangamo Biosciences Inc. Recent Developments
  67. 7.12 Lonza Group Limited
  68. 7.12.1 Lonza Group Limited Company Information
  69. 7.12.2 Lonza Group Limited Business Overview
  70. 7.12.3 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Lonza Group Limited CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  72. 7.12.5 Lonza Group Limited Recent Developments
  73. 7.13 Integrated DNA Technologies
  74. 7.13.1 Integrated DNA Technologies Company Information
  75. 7.13.2 Integrated DNA Technologies Business Overview
  76. 7.13.3 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Integrated DNA Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  78. 7.13.5 Integrated DNA Technologies Recent Developments
  79. 7.14 New England Biolabs
  80. 7.14.1 New England Biolabs Company Information
  81. 7.14.2 New England Biolabs Business Overview
  82. 7.14.3 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  83. 7.14.4 New England Biolabs CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  84. 7.14.5 New England Biolabs Recent Developments
  85. 7.15 Origene Technologies
  86. 7.15.1 Origene Technologies Company Information
  87. 7.15.2 Origene Technologies Business Overview
  88. 7.15.3 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Origene Technologies CRISPR and CRISPR-Associated (Cas) Genes Product Portfolio
  90. 7.15.5 Origene Technologies Recent Developments
8 North America
  1. 8.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue (2021-2032)
  2. 8.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2032)
  3. 8.2.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026)
  4. 8.2.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032)
  5. 8.3 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032)
  6. 8.4 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2032)
  7. 8.4.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026)
  8. 8.4.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032)
  9. 8.5 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032)
  10. 8.6 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
  11. 8.6.1 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021-2026)
  13. 8.6.3 North America CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue (2021-2032)
  2. 9.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2032)
  3. 9.2.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026)
  4. 9.2.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032)
  5. 9.3 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032)
  6. 9.4 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2032)
  7. 9.4.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026)
  8. 9.4.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032)
  9. 9.5 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032)
  10. 9.6 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
  11. 9.6.1 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021-2026)
  13. 9.6.3 Europe CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China CRISPR and CRISPR-Associated (Cas) Genes Revenue (2021-2032)
  2. 10.2 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2032)
  3. 10.2.1 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026)
  4. 10.2.2 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032)
  5. 10.3 China CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032)
  6. 10.4 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2032)
  7. 10.4.1 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026)
  8. 10.4.2 China CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032)
  9. 10.5 China CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue (2021-2032)
  2. 11.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2032)
  3. 11.2.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026)
  4. 11.2.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032)
  5. 11.3 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032)
  6. 11.4 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2032)
  7. 11.4.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026)
  8. 11.4.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032)
  9. 11.5 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032)
  10. 11.6 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
  11. 11.6.1 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021-2026)
  13. 11.6.3 Asia CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue (2021-2032)
  2. 12.2 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Type (2027-2032)
  5. 12.3 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Application (2027-2032)
  9. 12.5 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country
  11. 12.6.1 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA CRISPR and CRISPR-Associated (Cas) Genes Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst